Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

2002 • 4,805 citations

COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER

2002 • 3,803 citations

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

2000 • 2,156 citations

Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

2000 • 1,359 citations

Molecular mechanism of nucleotide excision repair

1999 • 1,118 citations

Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group

2003 • 946 citations

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

2002 • 667 citations

ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy

2001 • 608 citations

Aging and Genome Maintenance: Lessons from the Mouse?

2003 • 556 citations

ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.

1998 • 512 citations

The Structure-Specific Endonuclease Ercc1-Xpf Is Required To Resolve DNA Interstrand Cross-Link-Induced Double-Strand Breaks

2004 • 483 citations

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.

1994 • 439 citations

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

2001 • 348 citations

Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

2004 • 344 citations

RRM1 Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non–Small-Cell Lung Cancer

2006 • 338 citations

Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.

2003 • 313 citations

Clinical Model to Predict Survival in Chemonaive Patients With Advanced Non–Small-Cell Lung Cancer Treated With Third-Generation Chemotherapy Regimens Based on Eastern Cooperative Oncology Group Data

2004 • 253 citations

An Analysis of DNA Repair as a Determinant of Survival in Patients With Non-Small-Cell Lung Cancer

2002 • 172 citations

Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: A review of molecular epidemiological studies

2005 • 146 citations

Activity of Docetaxel in Platinum-Treated Non–Small-Cell Lung Cancer: Results of a Phase II Multicenter Trial

2000 • 135 citations

Reduced hematopoietic reserves in DNA interstrand crosslink repair-deficient Ercc1−/− mice

2005 • 132 citations

Gene Expression as a Predictive Marker of Outcome in Stage IIB-IIIA-IIIB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional Surgery

2004 • 128 citations

The Structure of the Human ERCC1/XPF Interaction Domains Reveals a Complementary Role for the Two Proteins in Nucleotide Excision Repair

2005 • 124 citations

Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin

2002 • 119 citations

Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy.

1995 • 115 citations

Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin

2004 • 90 citations

Tissue specific mutagenic and carcinogenic responses in NER defective mouse models

2006 • 64 citations

XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: Role of ERCC1 in homologous recombination repair

2006 • 61 citations